A new study explores why the same mutation in the BRAF gene leads to different therapeutic responses to its inhibitors in melanoma and colorectal cancer
Researchers from the B·ARGO at IGTP and ICO have conducted a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer, published in the journal BBA Reviews on Cancer.
